Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
1998-10-16
2001-11-20
Russel, Jeffrey E. (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C435S015000, C435S029000, C514S002600
Reexamination Certificate
active
06319898
ABSTRACT:
BACKGROUND OF THE INVENTION
This application relates to a method for inhibiting eukaryotic protein kinases using lipopeptide biosurfactant compounds such as surfactin or viscosin.
Kinase and phosphatase enzymes play important roles in the regulation of both eukaryotic and prokaryotic cells. For example, in eukaryotic cells, the control of proliferation and differentiation is achieved by multiple signal transduction pathways that are regulated by the coordinated action of protein kinases and phosphatases.
Kinase activity in eukaryotes can be classified as one of three types: those enzymes which phosphorylate tyrosine residues; those which are specific for serine or threonine residues; and those which have dual specificity for both tyrosine and serine/threonine residues. Because of the importance of these enzymes in eukaryotic regulatory processes, it would be highly desirable to be able to inhibit kinases of the various classes selectively to assist in the elucidation of kinase and phosphatase mediated pathways, particularly those that may be of medical significance. In addition, selective kinase or phosphatase inhibitors have potential uses as therapeutics. For example, it has been reported that a tyrosine kinase blocker designated AG-940 specifically inhibits the Jak-2 protein tyrosine kinase which is deregulated and constitutively activated in the leukemic cells of acute lymphoblastic leukemia (ALL) patients. Meydan, et al. “Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor”,
Nature
379: 645-648 (1996). This inhibition induced changes in cells consistent with entry into apoptosis when tested in vitro. Further, the intravenous administration of the inhibitor into mice previously injected with ALL cells has been shown to be effective to eradicate the ALL cells from the marrow.
Notwithstanding the potential uses of kinase and phosphatase inhibitors, the number of known and characterized inhibitors is quite small. Staurosporine and K-252a are known to act as generalized kinase inhibitors, while herbimycin and radicol specifically inhibit tyrosine kinases, albeit with fairly low effectiveness. There are few if any known specific inhibitors for the MAP kinase family, an important group of enzymes thought to be central in the transmission of a wide variety of signals received at the cellular membrane to the transcriptional and replication machinery of the nucleus.
To facilitate the identification of new kinase and phosphatase inhibitors, we have developed an assay which is described in our prior U.S. Pat. No. 5,770,392, issued Jun. 23, 1998, and PCT Publication No. WO98/17822 claiming priority therefrom, which are incorporated herein by reference.
The assay offers a simple and effective pre-screening tool which is easily stored, and which lends itself to automated, high-throughput screening. Further, materials selected for further evaluation as a result of the assay are already known to be effective in the cell, unlike activities based on in vitro assay systems. Most importantly, the assay system is not affected by compounds in the materials being tested that are cytotoxic to mammalian cells, thus interfering with assays using mammalian cells, and avoids problems with protease contaminants that do not interfere with microbial morphological assays but are a serious problem with animal cell and isolated receptor assays.
This assay basically involves the steps of:
adding the material to be tested for kinase inhibitory activity to a growing culture of a prokaryotic organism such as a streptomycete;
allowing the culture to grow for a period of time in the presence of the material; and
observing the culture for altered development relative to development of the prokaryotic organism grown in the absence of the material. Observation of altered development is indicative that the material has activity as an inhibitor of post-translational protein phosphorylation. In particular, the material to be tested can be added to a growing culture of the prokaryotic organism by placing a carrier disk bearing the material on a freshly seeded plate. Inhibition of the development of aerial mycelia and spore formation is an indicator that the material has activity as an inhibitor of post-translational protein phosphorylation.
SUMMARY OF THE INVENTION
Using the assay method of our prior invention, we have screened a number of bacterial cultures for the ability to inhibit sporulation of our preferred tester strain Streptomyces 85E. Evaluations of the cultures which tested positive in this assay have led to the discovery that lipopeptide biosurfactants such as surfactin and viscosin are effective inhibitors of eukaryotic protein kinase activity. Thus, the present invention provides a method for inhibiting eukaryotic protein kinase activity present in a sample or organism comprising the step of adding to the sample or organism an effective inhibitory amount of a lipopeptide biosurfactant.
REFERENCES:
patent: 5143839 (1992-09-01), Blumberg et al.
patent: 5169862 (1992-12-01), Burke, Jr. et al.
patent: 5451518 (1995-09-01), Kolesnick
patent: 5770392 (1998-06-01), Davies et al.
Laycock et al. Viscosin, A Potent Peptidolipid Biosurfactant . . . J. Agric. Food Chem. vol. 39, No. 3, pp. 483-489, 1991.*
Loing et al., Assessing Delivery of Lipopeptides into the Cytoplasm . . . Peptide Research. vol. 9, No. 5, pp. 229-232, 1996.*
Av-Gay, Y. and Davies, J. 1997 Components of eukaryotic-like protein signaling pathways inMycobacterium tuberculosis. Microbial & Comparative Genomics 2:63-73.
Georgiou, G, Lin, S-C.,and Sharma, M. 1992 Surface-active compounds from microorganisms. Biotechnology 10:60-65.
Gerrard, J., Lloyd, R., Barsby, T., Haden, P., Kelly, M and Anderson, R. 1997 Massotolides A-H, antimycobacterial cyclic depsipeptides produced by two Pseudomonads isolated from marine habitats. J. Nat. Prod. 60:223-229.
Lauterwein, M., Oethinger, M., Belsner, K., Peters, T. and Marrc, R. 1995 In vitro activities of the lichen secondary metabolites vulpinic acid, (+)-usnic acid and (31)-usnic acid against aerobic and anacrobic microorganisms. Antimicrobial Agents and Chemotherapy 39:2541-2543.
Stachelhaus, T., Schneider, A. and Marahiel, M. 1996 Engineered biosynthesis of peptide antibiotics. Biochemical Pharmacology 52:177-186.
Toraya, T., Maoka, T., Tsuji, H. and Kobayashi, M. 1995 Purification and structural determination of an inhibitor of starfish ocytc maturation from a Bacillus species. Applied and Environmental Micro. 5:1799-1804.
Natsume et al. Calcium Signal Modulators InhibitAerila myceliumFormation inStreptomyces alboniger' , J. Antibiotics 45: 1026-1028 (1992).
Hong et al., “Effects of protein kinase inhibitors on in vitroprotein phosphorylation and cellular differentiation ofStreptomyces griseus”, Mol. Gen. Genetics 236: 347-354 (1993).
Kennelly et al., “Fancy Meeting You Here! A Fresh Look at ‘Prokaryotic’ Protein Phosphorylation”, J. Bacteriol. 178: 4759-4764 (1996).
Karin et al., “Transcriptional control by protein phosphorylation: signal transmission from cell surface to nucleus”,Current Biology5: 747-757 (1995).
Ray, L.B., “Signals and Communiction,”Science268: 183 (1995).
Casey, P.J., “Protein Lipidation in Cell Signaling”,Science268: 224-225 (1995).
Burbulys et al., “Initiation of Sporulation in B. subtilis Is controlled by a Multicomponent Phosphrelay”Cell64: 545-552 (1991).
Stock et al., “Protein Phosphorylation and Regulation of Adaptive Responses in Bacteria”,Micriobiol. Reviews53: 450-490 (1989).
South et al., “Tyrosine Kinase sctivity inPseudomonas aeruginosa”,Molecular Microbiol. 12: 903-910 (1994).
Chow et al., “Protein tyrosine phosphorylation inMycobacterijm tuberculosis”,FEMS Microbiol. Lett. 124: 203-208 (1994).
Li et al., “Cloning, Purification and Properties of a Phosphotyrosine Protein Phosphatase fromStreptomyces coelicolorA3(2)”,J. Bactoeriol.178: 136-142 (1996).
Frasch et al., “Tyrosine Kinase inMyxococcus xanthus, a Multicellular Prokaryote”, preprint of article submitted toJ. Bacteriol(1996).
Zhang, C-C., “Bacterial Signalling Involving Eukaryotic-typ
Davies Julian E.
Saxena Geeta
Waters Barbara
Pennie & Edmonds LLP
Russel Jeffrey E.
Terragen Diversity, Inc.
LandOfFree
Method for inhibiting eukaryotic protein kinases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for inhibiting eukaryotic protein kinases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for inhibiting eukaryotic protein kinases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2583871